RXRX Stock Cash Flow Statements

Recursion Pharmaceuticals . Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Recursion Pharmaceuticals . Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30	2022-06-30	2022-03-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities
net income	-171,897,000	-202,487,000	-95,842,000	-97,540,000	-91,373,000	-93,017,000	-76,726,000	-65,327,000	-60,445,000	-65,560,000	-55,979,000	-47,428,000	-43,401,000	-30,717,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	23,849,000	19,331,000	7,198,000	8,968,000	7,377,000	7,578,000	5,543,000	3,728,000	2,989,000	2,786,000	2,767,000	2,436,000	2,331,000	1,402,000
stock-based compensation	26,159,000	36,058,000	18,253,000	16,524,000	16,127,000	16,792,000	11,811,000	8,814,000	8,907,000	5,675,000	5,632,000	3,363,000	5,317,000	1,821,000
asset impairment	0	5,956,000	0	0	108,000
lease expense	5,625,000	6,130,000	5,580,000	3,103,000	2,472,000	2,023,000	2,003,000	1,988,000	1,990,000	2,015,000	1,742,000
loss on disposal of a business	0	4,502,000
other	4,693,000	4,405,000	2,920,000	-3,010,000	-560,000	-1,853,000	23,000	716,000	-217,000	192,000	402,000	464,000	2,375,000	101,000
changes in operating assets and liabilities:
other receivables and assets	25,407,000	4,839,000	-939,000	736,000	-1,040,000	-203,000	-814,000	-317,000	3,777,000	-1,800,000	-7,551,000
prepaid data assets	2,470,000	27,131,000
accrued data liability
unearned revenue	-13,621,000	-9,762,000	3,917,000	-12,636,000	-13,655,000	-10,160,000	-11,066,000	-12,134,000	-13,053,000	-7,653,000	144,701,000	-2,500,000	-2,500,000	-2,500,000
accounts payable	-4,837,000	3,692,000	-1,513,000	-1,342,000	1,168,000	2,186,000	-2,517,000	-339,000	714,000	-986,000	1,344,000	3,130,000	71,000	2,051,000
accrued development expense	-754,000	599,000	-445,000	-1,905,000	-273,000	-1,356,000	1,071,000	676,000	819,000	1,464,000	1,413,000	918,000	1,822,000	-1,216,000
accrued expenses and other current liabilities	11,378,000	-26,591,000	6,349,000	7,507,000	-18,857,000	7,579,000	6,203,000	-9,846,000
lease liabilities	-5,148,000	-5,760,000
net cash from operating activities	-76,418,000	-131,957,000	-59,225,000	-82,219,000	-102,300,000	-72,920,000	-67,467,000	-73,316,000	-54,541,000	-61,623,000	77,388,000	-33,048,000	-33,653,000	-30,755,000
capex	-3,150,000	-1,832,000	-4,562,000	-1,182,000	-6,653,000	-745,000	-3,968,000	-5,175,000	-8,263,000	-16,475,000	-4,342,000	-9,706,000	-6,212,000	-19,416,000
free cash flows	-79,568,000	-133,789,000	-63,787,000	-83,401,000	-108,953,000	-73,665,000	-71,435,000	-78,491,000	-62,804,000	-78,098,000	73,046,000	-42,754,000	-39,865,000	-50,171,000
cash flows from investing activities
purchases of property and equipment	-3,150,000	-1,832,000	-4,562,000	-1,182,000	-6,653,000	-745,000	-3,968,000	-5,175,000	-8,263,000	-16,475,000	-4,342,000	-9,706,000	-6,212,000	-19,416,000
purchase of an intangible asset			0			-82,000	0	-165,000
decrease in cash related to disposal of a business	0	-4,438,000
purchases of investments	-500,000	-1,000,000
net cash from investing activities	-5,808,000	-7,270,000	-4,562,000	-4,182,000	-6,653,000	-347,000	-2,053,000	-5,340,000	52,984,000	4,940,000	143,304,000	-193,873,000	-6,212,000	-19,416,000
cash flows from financing activities
proceeds from issuance of common shares, net of issuance costs	100,000,000	41,024,000	16,968,000	261,546,000	10,873,000
proceeds from equity incentive plans	2,743,000	1,550,000	1,781,000	1,602,000	3,050,000	3,789,000	3,811,000	1,946,000	2,360,000	2,690,000	2,106,000
repayment of long-term debt and finance lease liabilities	-2,084,000	-2,047,000
net cash from financing activities	97,659,000	40,527,000	16,462,000	263,122,000	13,897,000	53,765,000	3,787,000	1,922,000	2,337,000	2,668,000	2,084,000	-11,095,000	463,705,000	2,134,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	9,255,000	4,833,000	403,000	-118,000	-219,000	-115,000	181,000	-2,000
net change in cash, cash equivalents and restricted cash	24,688,000	-93,867,000	-46,922,000	176,603,000	-95,275,000	-19,617,000	-65,552,000	-76,736,000	780,000	-54,015,000	222,776,000	-238,016,000	423,840,000	-48,037,000
cash, cash equivalents and restricted cash, beginning of period	0	603,024,000	0	0	401,425,000	0	0	559,112,000	0	0	295,349,000	0	0	267,167,000
cash, cash equivalents and restricted cash, end of period	24,688,000	509,157,000	-46,922,000	176,603,000	306,150,000	-19,617,000	-65,552,000	482,376,000	780,000	-54,015,000	518,125,000	-238,016,000	423,840,000	219,130,000
supplemental schedule of non-cash investing and financing activities
accrued property and equipment	-883,000	1,146,000	-313,000	469,000	80,000		-238,000	244,000	-1,081,000	-154,000	4,328,000	-350,000	58,000	705,000
purchase of an equity investment	0	4,438,000
net cash and restricted cash acquired in the acquisition of a business						0
sales and maturities of investments									61,547,000	21,415,000	147,646,000
issuance of shares for the acquisitions of businesses						-7,766,000
financed equipment purchase						0	0	1,214,000
operating lease liabilities				-2,624,000	-3,794,000	-2,508,000	-2,998,000	-2,444,000	-2,115,000	-1,547,000	-1,265,000
repayment of long-term debt				-26,000	-26,000	-24,000	-24,000	-24,000	-23,000	-22,000	-22,000	-12,737,000	-20,000	-20,000
right-of-use asset additions and modifications					3,266,000	164,000	640,000	3,520,000	-40,000
supplemental schedule of cash flow information
cash paid for operating leases					3,955,000	2,508,000	2,998,000	2,444,000	2,115,000	1,547,000	1,265,000
fixed asset impairment						19,000	0	1,169,000	0
proceeds from private placement of stock
cash paid for interest						11,000	12,000	13,000	14,000	14,000	14,000	125,000	286,000	254,000
loss on debt extinguishment
accrued expenses, deferred rent and other current liabilities									2,093,000	1,070,000	-15,903,000	10,126,000	-136,000	1,133,000
proceeds from initial public offering of common stock, net of issuance costs												0
conversion of preferred stock to common stock												0
deferred issuance costs recorded in equity												0
right-of-use asset additions											1,548,000
accounts receivable												16,000	13,000	85,000
acquisition of a business
proceeds from note receivable
proceeds from sale of preferred stock, net of issuance costs
proceeds from convertible notes
supplemental disclosure of non—cash investing and financing information
conversion of convertible notes to equity
supplemental disclosure of cash flow information
other assets													455,000	-2,915,000
proceeds from exercise of stock options													824,000	2,154,000
deferred issuance costs														2,997,000

We provide you with 20 years of cash flow statements for Recursion Pharmaceuticals . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Recursion Pharmaceuticals . stock. Explore the full financial landscape of Recursion Pharmaceuticals . stock with our expertly curated income statements.

The information provided in this report about Recursion Pharmaceuticals . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.